tiprankstipranks
Target upgraded, CVS downgraded: Wall Street’s top analyst calls
PremiumThe FlyTarget upgraded, CVS downgraded: Wall Street’s top analyst calls
2M ago
Lyra Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Lyra Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
2M ago
Lyra Therapeutics downgraded to Underperform from Buy at BofA
PremiumThe Fly
Lyra Therapeutics downgraded to Underperform from Buy at BofA
2M ago
Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
PremiumPress ReleasesLyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
2M ago
Lyra Therapeutics Navigates High-Stakes Clinical Trials Amid Safety and Efficacy Challenges
PremiumCompany Announcements
Lyra Therapeutics Navigates High-Stakes Clinical Trials Amid Safety and Efficacy Challenges
2M ago
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
PremiumPress Releases
Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
2M ago
Lyra Therapeutics management to meet with Cantor Fitzgerald
PremiumThe FlyLyra Therapeutics management to meet with Cantor Fitzgerald
3M ago
Lyra Therapeutics price target lowered to $11 from $12 at BofA
PremiumThe Fly
Lyra Therapeutics price target lowered to $11 from $12 at BofA
3M ago
Lyra Therapeutics files $300M mixed securities shelf
PremiumThe Fly
Lyra Therapeutics files $300M mixed securities shelf
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100